Tamoxifen for breast-cancer prevention

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2003-01, Vol.361 (9352), p.177-177
Main Author: Cykert, Samuel
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - mortality
Breast Neoplasms - prevention & control
Clinical Trials as Topic
Female
Humans
Risk Assessment
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63
cites cdi_FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63
container_end_page 177
container_issue 9352
container_start_page 177
container_title The Lancet (British edition)
container_volume 361
creator Cykert, Samuel
description
doi_str_mv 10.1016/S0140-6736(03)12210-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72976863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673603122106</els_id><sourcerecordid>278679551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlZ_glI8FD2sTnbz0ZxEil9Q8GAFb2E3mcCW7m5Ndov-e9MPFLz0NDPwzMzLQ8g5hRsKVNy-AWWQCJmJK8iuaZrSOB2QPmWSJZzJj0PS_0V65CSEOQAwAfyY9GjKMxrbPhnN8qr5Kh3WQ9f4YeExD21i8tqgHy49rrBuy6Y-JUcuXwQ829UBeX98mE2ek-nr08vkfpoYRkEkwkmFhhtp0AhlUQjGeGELLq0zmTO2kKmxLBeguCqsKxTmzqTcWWCmQJENyGh7d-mbzw5Dq6syGFws8hqbLmiZKinGIovg5T9w3nS-jtk0VQoyiJL2QemYgYwQ30LGNyF4dHrpyyr335qCXqvWG9V67VFDpjeq9Trqxe54V1Ro_7Z2biNwtwUwCluV6HUwJUaxtvRoWm2bcs-LHydsjKs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199028407</pqid></control><display><type>article</type><title>Tamoxifen for breast-cancer prevention</title><source>Business Source Ultimate</source><source>ScienceDirect Journals</source><creator>Cykert, Samuel</creator><creatorcontrib>Cykert, Samuel</creatorcontrib><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(03)12210-6</identifier><identifier>PMID: 12531605</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Breast Neoplasms - mortality ; Breast Neoplasms - prevention &amp; control ; Clinical Trials as Topic ; Female ; Humans ; Risk Assessment ; Tamoxifen - adverse effects ; Tamoxifen - therapeutic use</subject><ispartof>The Lancet (British edition), 2003-01, Vol.361 (9352), p.177-177</ispartof><rights>2003 Elsevier Ltd</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts Jan 11 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63</citedby><cites>FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12531605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cykert, Samuel</creatorcontrib><title>Tamoxifen for breast-cancer prevention</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - prevention &amp; control</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Risk Assessment</subject><subject>Tamoxifen - adverse effects</subject><subject>Tamoxifen - therapeutic use</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LAzEQhoMotlZ_glI8FD2sTnbz0ZxEil9Q8GAFb2E3mcCW7m5Ndov-e9MPFLz0NDPwzMzLQ8g5hRsKVNy-AWWQCJmJK8iuaZrSOB2QPmWSJZzJj0PS_0V65CSEOQAwAfyY9GjKMxrbPhnN8qr5Kh3WQ9f4YeExD21i8tqgHy49rrBuy6Y-JUcuXwQ829UBeX98mE2ek-nr08vkfpoYRkEkwkmFhhtp0AhlUQjGeGELLq0zmTO2kKmxLBeguCqsKxTmzqTcWWCmQJENyGh7d-mbzw5Dq6syGFws8hqbLmiZKinGIovg5T9w3nS-jtk0VQoyiJL2QemYgYwQ30LGNyF4dHrpyyr335qCXqvWG9V67VFDpjeq9Trqxe54V1Ro_7Z2biNwtwUwCluV6HUwJUaxtvRoWm2bcs-LHydsjKs</recordid><startdate>20030111</startdate><enddate>20030111</enddate><creator>Cykert, Samuel</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20030111</creationdate><title>Tamoxifen for breast-cancer prevention</title><author>Cykert, Samuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - prevention &amp; control</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Risk Assessment</topic><topic>Tamoxifen - adverse effects</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cykert, Samuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cykert, Samuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tamoxifen for breast-cancer prevention</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2003-01-11</date><risdate>2003</risdate><volume>361</volume><issue>9352</issue><spage>177</spage><epage>177</epage><pages>177-177</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12531605</pmid><doi>10.1016/S0140-6736(03)12210-6</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2003-01, Vol.361 (9352), p.177-177
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_72976863
source Business Source Ultimate; ScienceDirect Journals
subjects Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - mortality
Breast Neoplasms - prevention & control
Clinical Trials as Topic
Female
Humans
Risk Assessment
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
title Tamoxifen for breast-cancer prevention
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A25%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tamoxifen%20for%20breast-cancer%20prevention&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Cykert,%20Samuel&rft.date=2003-01-11&rft.volume=361&rft.issue=9352&rft.spage=177&rft.epage=177&rft.pages=177-177&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(03)12210-6&rft_dat=%3Cproquest_cross%3E278679551%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4106-6f79ec5c7cec69de66445bdb57dfc3fcdb72cd4a60959bdfb9eafc25fd04cbe63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=199028407&rft_id=info:pmid/12531605&rfr_iscdi=true